Medicare, the government administered medical insurance has just been advised by the government that they will have to cover the new prostate cancer vaccine that has been made available by Dendreon Corporation (NASDAQ:DNDN).
This new vaccine is already being covered by other major health providers such as Humana and Aetna. Medicare has been hesitant to cover this prostate cancer treatment due to its cost standing at a mere $93,000. For those covered by Medicare and need this treatment can now go ahead and seek it, since their insurance will cover the high cost of their treatment. All one will have to pay for is the minimal co-pay.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.